KERX Financial Facts

Basic and diluted net loss per common share: -0.22
Operating loss: -17.74M
See Full Income Statement

Other assets, net: 281K
Total liabilities and stockholders' equity: 60.77M
See Full Balance Sheet

Keryx Biopharmaceuticals Inc. (KERX) Earnings

  |   Expand Research on KERX
Next EPS Date 5/8/14 *Est. EPS Growth Rate -133.3% *Last Qtr.
Average EPS % Beat Rate -86.0% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +6.2% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. % Since Details
3/12/14 Q413 -$0.21-$0.16 -$0.05N/A$2.22M N/A -9.1% Details
11/4/13 Q313 -$0.19-$0.11 -$0.08N/A$2.22M N/A +21.3% Details
7/31/13 Q213 -$0.14-$0.10 -$0.04N/AN/A N/A 0% Details
5/7/13 Q113 -$0.03-$0.01 -$0.02$7M$5.83M N/A +68.5% Details
3/11/13 Q412 -$0.09-$0.08 -$0.01N/AN/A N/A +83.1% Details
11/8/12 Q312 -$0.08-$0.07 -$0.01N/AN/A N/A +467.9% Details
8/7/12 Q212 -$0.02-$0.09 +$0.07N/AN/A N/A +627.6% Details
5/8/12 Q112 -$0.13-$0.12 -$0.01N/AN/A N/A +854.6% Details